A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
The purpose of this study is to compare the effects, good and/or bad, of a combination of three drugs (lenalidomide, bortezomib and dexamethasone (RVD) with or without autologous stem cell transplantation, followed by lenalidomide therapy as a possible treatment for newly diagnosed multiple myeloma.
Participants between the ages of 18-65 that have untreated newly diagnosed Multiple Myeloma.
18 - 65
Healthy Volunteers Needed
Duration of Participation
Until disease progression
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Dana Farber Cancer Institute